Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.


Journal Article

OBJECTIVE: This post hoc analysis evaluated romiplostim self-administration (SA group) vs. romiplostim administration by a healthcare provider in a clinical setting (HCP group) in patients with chronic immune thrombocytopenia (ITP). METHODS: Outcomes from 3 ITP trials allowing self-administration in patients achieving a stable romiplostim dose for ≥3 consecutive weeks were compared. Evaluations were conducted for 12-wk treatment intervals. Efficacy endpoints included percentage of patients and weeks with platelets within the target range of 50-200 × 10(9) /L and safety. RESULTS: Baseline characteristics suggested less severe disease in the SA groups (n = 563) than in the HCP groups (n = 241). The SA groups had greater proportions of patients achieving the target platelet range (55-58% vs. 40-52%) and greater proportions of weeks with a platelet response (75-88% vs. 47-76%) than the HCP groups. The rate of romiplostim discontinuation was twofold to fivefold lower in the SA groups than in the HCP groups. Rates of duration-adjusted adverse events (AEs), serious AEs and treatment-related AEs were also lower in the SA groups. CONCLUSIONS: In conclusion, in adults with ITP receiving romiplostim, self-administration was comparable to healthcare provider administration in terms of efficacy and safety profiles, suggesting that self-administration of romiplostim is a feasible option for certain patients with ITP.

Full Text

Duke Authors

Cited Authors

  • Selleslag, D; Bird, R; Altomare, I; Giagounidis, A; Janssens, A; Pabinger, I; Pullarkat, V; Wei, H; Kreuzbauer, G

Published Date

  • February 2015

Published In

Volume / Issue

  • 94 / 2

Start / End Page

  • 169 - 176

PubMed ID

  • 25039799

Pubmed Central ID

  • 25039799

Electronic International Standard Serial Number (EISSN)

  • 1600-0609

Digital Object Identifier (DOI)

  • 10.1111/ejh.12415


  • eng

Conference Location

  • England